Kenya 'at high risk' of deadly Ebola

The World Health Organization (WHO) has classified Kenya as a "high-risk" country for the spread of the deadly Ebola virus.

Kenya was vulnerable because it was a major transport hub, with many flights from West Africa, a WHO official said.

This is the most serious warning to date by the WHO that Ebola could spread to East Africa.

Health experts are battling to contain the outbreak in West Africa, where it has killed more than 1,000 people.

Canada said it would donate up to 1,000 doses of an experimental Ebola vaccine to help fight the outbreak.

Airport health checks

In Sierra Leone, a doctor who treated patients infected with Ebola has died, reports the BBC's Umaru Fofana from the capital, Freetown.

Dr Modupeh Cole is the second Sierra Leonean doctor to die of the disease.

In Nigeria, Africa's most populous state, a third Ebola-related death was reported on Tuesday.

In other developments:

Germany has ordered all its citizens, except health workers, to leave Guinea, Sierra Leone and Liberia, the three states where the outbreak has been the deadliest.

Guinea-Bissau has decided to shut its border with Guinea, Reuters news agency reports.

Ghana has delayed the opening of universities and colleges by at least two weeks to put in place measures to screen students arriving from Ebola-hit countries.

The WHO's country director for Kenya, Custodia Mandlhate, said the East African state was "classified in group two; at high risk of transmission".

Health checks at the main airport in the capital, Nairobi, have been stepped up in recent weeks.

'Global resource'

The government said it would not ban flights from the four countries hit by Ebola.

"We do not recommend ban of flights because of porous borders," health cabinet secretary James Macharia said.

Kenya receives more than 70 flights a week from West Africa.

The West African regional body, Ecowas, said one of its officials, Jatto Asihu Abdulqudir, had died of Ebola in Nigeria.

The 36-year-old had been in contact with Patrick Sawyer, the Liberian government employee who was the first to be killed by the virus in Nigeria on 25 July, Ecowas said in a statement.

Mr Sawyer had flown in from Liberia, when he was diagnosed with Ebola after collapsing at the airport in Lagos, the biggest city in sub-Saharan Africa.



This is the first time West Africa has been affected by Ebola, with previous outbreaks hitting East and Central Africa.

There is no cure for Ebola and the outbreak has been declared a global health emergency by the WHO.

On Tuesday, it approved the use of untested drugs on Ebola patients.

However, experts say supplies of both the vaccine and the experimental drug Zmapp are limited and it could take months to develop more supplies.

Dr Gregory Taylor, deputy head of Canada's Public Health Agency, said he saw the vaccines as a "global resource".

He said he had been advised that it would make sense for healthcare workers to be given the vaccine, given their increased risk of contracting the disease.

Zmapp has been used on two US aid workers who have shown signs of improvement, although it is not certain what role the medication played in this.

A Roman Catholic priest, infected with Ebola in Liberia, who died after returning home to Spain is also thought to have been given the drug.

What drugs exist currently ?

There are a handful of drugs that have been shown to work well in animals.

One is Zmapp - the drug requested by the Liberian government. This contains a cocktail of antibodies that attack proteins on the surface of the virus.

Only one drug has moved on to early safety testing in humans. Known as TKM-Ebola, this interrupts the genetic code of the virus and prevents it from making disease-causing proteins.

The drug was trialled in healthy volunteers at the beginning of 2014 but the American medicines regulator asked for further safety information. The manufacturer says human studies may soon resume.

Another option would be to use serum from individuals who have survived the virus - this is a part of the blood that may contain particles able to neutralise the virus.

Vaccines to protect against acquiring the disease have also been shown to work in primates. American authorities are considering fast-tracking their development and say they could be in use in 2016. Trials are likely to start soon, according to the WHO.

But experts warn that ultimately the only way to be sure a drug or vaccine is effective is to see if it works in countries affected by Ebola.



Symptoms include high fever, bleeding and central nervous system damage

Fatality rate can reach 90% - but the current outbreak is about 55%

Incubation period is two to 21 days

There is no vaccine or cure

Supportive care such as rehydrating patients who have diarrhoea and vomiting can help recovery

Fruit bats are considered to be virus' natural host